Lara Sullivan - 31 Mar 2022 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Executive Officer, Director
Signature
/s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan
Issuer symbol
PYXS
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 16:15:53 UTC
Previous filing
07 Oct 2021
Next filing
15 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Award $0 +742,574 +249% $0.000000 1,041,363 31 Mar 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.